No surprise there. Here are a few of Doug's headli
Post# of 154112
(Total Views: 695)
Posted On: 08/15/2020 3:24:05 AM
No surprise there. Here are a few of Doug's headlines and "reporting". Keep in mind, this guy is the News Editor of Seeking Alpha, not an opinion columnist:
-CytoDyn reports "strong results" with leronlimab in COVID-19 (What objective News Editor would use quotation marks around strong results? Seems like a sly attempt to instill fear, uncertainty, and doubt)
-CytoDyn down 9% as CEO moves to sell stock while touting COVID-19 drug (Includes link to AF's stat news article which is inappropriate. This would never pass editorial muster at a serious news institution. He is also implying motive, which makes it subjective in nature)
-CytoDyn down 32% on bearish Citron report (This time he links to Andrew Left's report)
-FDA rejects CytoDyn's leronlimab application for HIV (Why not say "issued a Refusal to File letter" in the headline as he did in the body of his report? Using "rejects" gives the headline a negative slant)
-CytoDyn announces "positive" results from mid-stage COVID-19 study (See above)
-"clinically significant"
-CEO emphasizing the NEWS2 secondary endpoint which was met, not the primary endpoint which was missed. (Misleading in its brevity)
-Premature to know if the ongoing Phase 2 in severely and critically ill COVID-19 patients will be a "double, triple or home run." An interim analysis will be conducted after 195 patients have been treated. (Mockery?)
Remember, this guy is the NEWS EDITOR for a very influential website.
I'm no conspiracy nut, but there are definitely red flags out there. Aside from blafarm's example, does Douglas House treat other companies in this fashion, incessantly? Honest question.
-CytoDyn reports "strong results" with leronlimab in COVID-19 (What objective News Editor would use quotation marks around strong results? Seems like a sly attempt to instill fear, uncertainty, and doubt)
-CytoDyn down 9% as CEO moves to sell stock while touting COVID-19 drug (Includes link to AF's stat news article which is inappropriate. This would never pass editorial muster at a serious news institution. He is also implying motive, which makes it subjective in nature)
-CytoDyn down 32% on bearish Citron report (This time he links to Andrew Left's report)
-FDA rejects CytoDyn's leronlimab application for HIV (Why not say "issued a Refusal to File letter" in the headline as he did in the body of his report? Using "rejects" gives the headline a negative slant)
-CytoDyn announces "positive" results from mid-stage COVID-19 study (See above)
-"clinically significant"
-CEO emphasizing the NEWS2 secondary endpoint which was met, not the primary endpoint which was missed. (Misleading in its brevity)
-Premature to know if the ongoing Phase 2 in severely and critically ill COVID-19 patients will be a "double, triple or home run." An interim analysis will be conducted after 195 patients have been treated. (Mockery?)
Remember, this guy is the NEWS EDITOR for a very influential website.
I'm no conspiracy nut, but there are definitely red flags out there. Aside from blafarm's example, does Douglas House treat other companies in this fashion, incessantly? Honest question.
(8)
(0)